AI-Developed Antibody Shows Promising Early Trial Results
Absci Corporation announced positive interim Phase 1 data for ABS-201, an antibody designed using generative AI. The trial in healthy volunteers for androgenetic alopecia demonstrated a favorable safety and pharmacokinetic profile without serious adverse events. This investigational treatment is also being explored for endometriosis.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.